No. 37 Guo Xue Xiang Chengdu, Sichuan, 610041 ChinaThe Core Facility of Genetically Engineered Mice (GEM) is a nonprofit laboratory focusing on biomedicine and genetics research to advance human health. Our mission is to discover the genetic basis for preventing, treating and curing human disease, and to enable research and education for the global biomedical community. Our work uses the mouse as a research tool. Because mice and humans share 95% of their genes, mice are an effective and efficient model for human diseases. Here, we: l conduct genetic research l provide scientific services and genetic resources to laboratories around the world l educate students of all ages through courses, internships and other programs

37 Guo Xue Xiang Chengdu Shi, Sichuan Sheng, 610000 ChinaThe Core Facility of Genetically Engineered Mice (GEM) is a nonprofit laboratory focusing on biomedicine and genetics research to advance human health. Our mission is to discover the genetic basis for preventing, treating and curing human disease, and to enable research and education for the global biomedical community. Our work uses the mouse as a research tool. Because mice and humans share 95% of their genes, mice are an effective and efficient model for human diseases. Here, we: l conduct genetic research l provide scientific services and genetic resources to laboratories around the world l educate students of all ages through courses, internships and other programs

Chengdu Shi, Sichuan Sheng ChinaChemPartner is a global, full-service life science CRO/CDMO with nearly 20 years of biopharmaceutical experience focused on supporting R&D and providing guidance for smaller biotechs and virtual companies. With a team of over 2000 scientists and experienced pharmaceutical executive leadership, ChemPartner is uniquely positioned to not only be a CRO/CDMO, but to be a true pharmaceutical alliance partner. Our integrated CRO services support fee-for-service projects or FTE teams in chemistry, biologics, biology, and DMPK, with many therapeutic sub-specialties (e.g. immunology, oncology, neuroscience, etc). Our CMC teams provide one-stop services for overall process development and IND application support for both small and biologics/large molecule development and manufacturing. ChemPartner serves a diverse global client base and has laboratories, business offices, and representatives in the US, Europe, China, and Japan. ChemPartner is well-positioned to be your partner to support and advance your projects quickly and efficiently with a focus on value and quality.

成都市双流区慧谷东2路8号1栋701 成都市, 四川省, 610200 ChinaShengshi Junlian is a biotechnology company focused on early drug discovery and optimization of antibodies, possessing leading 100% multi-site mutation efficiency and directed mutation control synthetic library technology. It has completed the synthesis of a real library of 300 billion biological macromolecule drugs. Based on a diverse compound library, it has established a high-throughput screening platform for antibody drugs and an AI-assisted drug development platform (ABLINK® BioAI for Scientists), forming drug development collaborations with dozens of leading domestic pharmaceutical companies, biotech firms, and research institutions. To date, it has completed over 300 commercial projects, with several service projects entering clinical stages, more than 10 projects completing licensing transfers, and multiple projects achieving milestone results.

701, Building 1, No. 8, Huigu East 2nd Road, Shuangliu District, Chengdu, Sichuan Province Chengdu City , Sichuan Province, 610200 ChinaShengshi Junlian is a biotechnology company focused on early drug discovery and optimization of antibodies, possessing leading 100% multi-site mutation efficiency and directed mutation control synthetic library technology. It has completed the synthesis of a real library of 300 billion biological macromolecule drugs. Based on a diverse compound library, it has established a high-throughput screening platform for antibody drugs and an AI-assisted drug development platform (ABLINK® BioAI for Scientists), forming drug development collaborations with dozens of leading domestic pharmaceutical companies, biotech firms, and research institutions. To date, it has completed over 300 commercial projects, with several service projects entering clinical stages, more than 10 projects completing licensing transfers, and multiple projects achieving milestone results.

四川省成都市双流区慧谷东2路8号1栋701 成都市, 四川省, 610200 ChinaShengshi Junlian is a biotechnology company focused on early drug discovery and optimization of antibodies, possessing leading 100% multi-site mutation efficiency and directed mutation control synthetic library technology. It has completed the synthesis of a real library of 300 billion biological macromolecule drugs. Based on a diverse compound library, it has established a high-throughput screening platform for antibody drugs and an AI-assisted drug development platform (ABLINK® BioAI for Scientists), forming drug development collaborations with dozens of leading domestic pharmaceutical companies, biotech firms, and research institutions. To date, it has completed over 300 commercial projects, with several service projects entering clinical stages, more than 10 projects completing licensing transfers, and multiple projects achieving milestone results.

Building 16, No.99 Haiwang Road, Wenjiang District, Chengdu, China 611130 chengdu, sichuan, 611130 ChinaAlpVHHs® specializes in developing and producing customized, high-performance alpaca nanobodies. We provide tailored single-domain antibody (VHH or sdAb) pre-discovery CRO services and innovative nanobody products as the next-generation RUO tools for life science research.

5th Floor, Building 10, No.139 Qingpi Road, Wenjiang District, Chengdu Chengdu, Sichuan Province, 611100 ChinaWe focuses on nanobody pre-discovery CRO. We are an innovative bio-technology enterprise with alpaca and camelid single domain antibody R&D, production and service. We have built our own 300 acres alpaca breeding base and passed the review of Amgen Laboratory Animal Welfare and Ethics Committee. We have built a complete nanobody discovery platform, including phage display nanobody discovery platform, NGS sequencing platform, yeast display nanobody discovery platform, nanobody affinity maturation and humanization, protein expression & purification platform, focusing on the pre-discovery of nanobody through a high-throughput combinatorial R&D platform. Currently, we have served about 500 nanobody pre-discovery projects from 200 pharmaceutical companies.

5th Floor, Building 10, No.139 Qingpi Road, Wenjiang District, Chengdu, Sichuan, China CHENGDU, Sichuan, 610000 ChinaWe focuses on nanobody pre-discovery CRO. We are an innovative bio-technology enterprise with alpaca and camelid single domain antibody R&D, production and service. We have built our own 300 acres alpaca breeding base and passed the review of Amgen Laboratory Animal Welfare and Ethics Committee. We have built a complete nanobody discovery platform, including phage display nanobody discovery platform, NGS sequencing platform, yeast display nanobody discovery platform, nanobody affinity maturation and humanization, protein expression & purification platform, focusing on the pre-discovery of nanobody through a high-throughput combinatorial R&D platform. Currently, we have served about 500 nanobody pre-discovery projects from 200 pharmaceutical companies.

West haike road,Cross-straits technological industry park Wenjiang, Chengdu 611130 ChinaChengdu Sino-Strong Pharmaceutical offers API, intermediates, and working standards in addition to offering custom synthesis services.

No. 198, Haida Road, Wenjiang District Chengdu City China Chengdu , Si Chuan, 611130 ChinaC Ray Therapeutics (Chengdu) Co.,Ltd. is dedicated to delivering end-to-end solutions for innovative radiopharmaceuticals to clients around the world. Our services span process development, quality research, preclinical evaluation, IND Enabling, clinical supply, and commercial scale cGMP production, all backed by a reliable, robust logistics network. As of 2024, we have raised over USD 187 million in total funding. C Ray Therapeutics has successfully delivered and continues to operate 100+ CRDMO projects, including 44 preclinical and molecular imaging CRO projects and 17 CDMO projects. Among these, 3 have entered the IND and IND-enabling stages, 9 have advanced to investigator-initiated trials (IITs), and 5 have entered the clinical supply stage, with 2 of them successfully progressing to a Phase III clinical study. The company has achieved comprehensive coverage of all critical links across the entire radiopharmaceutical R&D and manufacturing chain. As a dedicated CRDMO partner in radiopharmaceuticals, one of our core strengths is a stable, diversified supply of radionuclides. We are actively developing high-quality domestic sources while playing a leading role in integrating and fortifying the global supply chain—most notably securing access to challenging isotopes such as Ac-225. To date, we have supported the development of 16 Ac-225–labeled projects.

Hi-Tech Industry Park Zone, No.339, Xingshun Road, Jinniu District, Chengdu, Sichuan Province ChinaGB PHARMA provides API manufacturing, peptide products, amino acid derivatives, and reagent synthesis.

Tianfu International Ciological City Chengdu, Sichuan, 10010 ChinaGlotope stands firm in its local roots while reaching out to the global market. With dual headquarters in Beijing and Chengdu, we operate state-of-the-art radiopharmaceutical R&D and production centers in Jiangsu, Guangdong, and Sichuan. Our facilities boast over 100 advanced R&D and production hot cells and qualifications for handling a variety of radionuclides, including but not limited to 225Ac, 177Lu, 212Pb, 68Ga, 18F, 64Cu, 203Pb, and 89Zr. At Glotope, we provide adaptive and all-encompassing support to our global clientele, spanning the full spectrum of radiopharmaceutical development. From expedited PCC validation to IND submissions in China and US, from clinical trials to NDA approvals, and commercial-scale manufactering, we guarantee seamless and efficacious transitions at every phase. Our unparalleled expertise and cutting-edge facilities empower us to deliver superior solutions and prompt outcomes, driving innovation and revitalizing the radiopharmaceutical industry worldwide..

Building 6,No.8,Huigu 1st East Road Tianfu International Bio-Town, Shuangliu District Chengdu, Sichuan, 610200 ChinaHitGen Inc. is a rapidly developing biotech company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. It became a publicly listed company in Shanghai Stock Exchange in April 2020 (ticker code 688222.SH). HitGen has established a drug discovery research platform for small molecules and nucleic acid drug centered on the design, synthesis and screening of DNA encoded chemical libraries (DELs), fragment-based drug discovery (FBDD) and structure-based drug design (SBDD) technologies. HitGen's DELs currently contains more than 1 trillion novel, diverse, drug-like small molecules and macrocyclic compounds. These compounds are members of DELs synthesized from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and have yielded proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets. Through its acquisition of Cambridge UK based Vernalis R&D Ltd before the end of 2020, a leader in FBDD/SBDD, HitGen now has a research team of over 500 scientists and offers a full set of research capabilities from recombinant protein expression and purification, structural biology, assay development, screening, DEL synthesis, nucleic acid and small molecule chemical synthesis, computational and medicinal chemistry, biochemistry and biophysics, cell biology, in vivo pharmacology, DMPK, CMC, etc., to enable drug discovery research from target gene to IND filing. Meanwhile, HitGen has built an integrated RNA therapeutics R&D platform including experienced teams, research labs and technologies covering several key fields such as bioinformatics, organic chemistry and medicinal chemistry，RNA biology, molecular biology and cell biology, translational research and clinical research. The platform not only provides high quality services to support internal and external RNA therapeutics R&D projects, but also carries out siRNA sequence design, siRNA parallel synthesis and chemical modification/conjugation, mRNA and protein knock-down assays in both engineered cell lines and primary cell lines, stability test, off-target assessment, bio-distribution and other relate in vitro/in vivo assays for activity and toxicity study, etc. HitGen has also established its own pipelines in early stages to discover novel RNA therapeutics, aiming for providing new treatment for unmet medical needs in oncology and immunology. HitGen operates a flexible business model, ranging from a single capability-based fee for services (FFS，e.g., protein expression and purification, structural biology, bioinformatics, computational chemistry, medicinal chemistry, nucleic and organic chemistry, analytical chemistry， biophysics, PK, PD, etc.), DEL screening, DEL design, synthesis and characterization, integrated drug discovery projects, risk sharing projects, collaborative ventures to program out-licensing. HitGen has approximately 20 in-house drug discovery programs at different stages of research & development. HitGen is collaborating with pharmaceutical, biotech and chemical companies, foundations and research institutes in North America, Europe, Asia, Africa and Australia to enable the discovery and development of novel medicines and agrochemicals.

17, Zone 3, Ren Min Nanlu, Chengdu, 610041 ChinaHuaFaMei specializes in the export and distribution of API, intermediates, plant extracts, and chemical raw materials.

2 Floor Block A,Huaxi Building, No.5 LinYin Road Chengdu, 610041 ChinaHuaFaMei specializes in the export and distribution of API, intermediates, plant extracts, and chemical raw materials.

He Zuo Lu West High-tech District Chengdu Shi, Sichuan Sheng ChinaLan Pharmatech Ltd., founded in 2018, is a rapidly developing high-tech company focusing on active pharmaceutical ingredient (API), intermediates and impurities' design, manufacture and sales. Our manufacturing base locates at West High-tech Zone in Chengdu, with more than 300 sq. meters combined reactor volume, ranging from 30L to 2,000L of reactor size. Although established just for one year, we have partnered with institutes, such as sub-brunches of Chinese Academy of Sciences, and many local big pharmaceutical companies, having stable and long-term cooperation relations for their new drugs production.

88# Keyuan road, Hi-Tech Zone Chengdu, Sichuan, 610042 ChinaScientist.com is the world’s largest marketplace for medical research. We help pharmaceutical scientists discover life-saving medicines in less time and at lower cost. Our mission is to make it possible to cure all human disease by 2050. By connecting scientists and enabling them to exchange ideas and transact seamlessly online, Scientist.com is speeding up and reducing the cost of medical research. We were founded in 2007, launched our first research outsourcing marketplace in 2008 and built our first enterprise marketplace for Pfizer in 2009. Today, we operate enterprise marketplaces for 24 of the world’s top 30 pharmaceutical companies, 100+ biotechnology companies and the US National Institutes of Health (NIH).

Chengdu Shengnuo Biopharm Co. Ltd No.248, Segment1, Industrial Rd Dayi county, Chengdu, Sichuan ChinaShengnuo Peptide is a China-based peptide manufacturer that specializes in peptide API’s, R&D & cGMP custom peptides. Besides large scale GMP production of custom peptide and peptide APIs, Shengnuo continues to invest in new technology development which includes: unusual peptide modification and peptidomimetics synthesis.

Chengdu, Sichuan ChinaSichuan Industrial Institute of Antibiotics offers APIs, chromatography, chemical structure determination, amino acid analysis, and process development.

Park B4-501, No.88 South Keyuan Road Gaoxin District , Tianfu Life Science Park Chengdu, Sichuan , 610041 ChinaSichuan PriMed Shines Biotech Co., Ltd. (PriMed) is a partner of choice for translational medicine research. To build the best technology platform with translatable NHP models and access to large population of patients to enable translational research from NHP to human using imaging and other biomarkers. PriMed's research facilities are AAALAC accredited and GLP compliant, providing expertise from disease model validation to IND-enabling study design and execution for over 100 global partners. PriMed has extensive expertise and significant experience in non-human primate research, as well as identifying and developing specialized animal models of human disease, helping global biomedical research community solve challenges in Metabolic disease, Eye disease, Cardiovascular diseases, Alzheimer's disease, NAFLD/NASH, Autoimmune diseases and Kidney disease. PriMed has well-established multi-modality imaging capabilities and extensive expertise in developing and applying imaging biomarkers for drug discovery and development with 11 different imaging modalities available for studies. PriMed's research center has (n=~3000) rhesus/cynomolgous macaques with clearly pedigree and has set up a unique sizable (middle age/aged., equivalent to 40~70 years in human) NHP population (n= ~1500) with spontaneous metabolic, eye disease, cardiovascular, Alzheimer's disease phenotypes that translate well into clinical observations. PriMed has a plasma/tissue biobank and a database of over 7 year’s historical clinical data for all monkeys, including semiannual metabolic examination and treatment record.

#28 GaoPeng Avenue, Hi-Tech Development Zone , Chengdu 610041, China Chengdu, Sichuan, 610041 ChinaFounded in 2000, WestChina-Frontier PharmaTech Co., Ltd. (WCFP) is a professional GLP facility for new drug non-clinical research and evaluation in China. WCFP has a strong scientific, technical, regulatory and management team, and has established a global pharmacodynamics, pharmacokinetics and safety evaluation platform equipped with internationally advanced experimental, testing and analytical instruments and equipments. WCFP has successively obtained multiple international and domestic certifications, including AAALAC accreditation, OECD GLP certification from the European Union, CAP certification from the College of American Pathologists, and an FDA GLP inspection from the United States.

28, Gaopeng Road, New and Hi-tech Development Zone, ChengduFounded in 2000, WestChina-Frontier PharmaTech Co., Ltd. (WCFP) is a professional GLP facility for new drug non-clinical research and evaluation in China. WCFP has a strong scientific, technical, regulatory and management team, and has established a global pharmacodynamics, pharmacokinetics and safety evaluation platform equipped with internationally advanced experimental, testing and analytical instruments and equipments. WCFP has successively obtained multiple international and domestic certifications, including AAALAC accreditation, OECD GLP certification from the European Union, CAP certification from the College of American Pathologists, and an FDA GLP inspection from the United States.